"We are delighted with the FDA's decision to grant TXA709 a Qualified Infectious Disease Product designation as we continue to research its potential," said Gregory Mario, President and Chief Executive Officer of TAXIS Pharmaceuticals. "Pre-clinical data shows TXA709 to be a promising and potentially revolutionary antibiotic."
TXA709 is a prodrug, a biologically inactive compound that can be metabolized in the body to produce a drug, TXA707, a derivative of benzoic acid that disrupts the form and function of the bacterial protein FtsZ, which plays an essential role in bacterial cell division. The inhibition of FtsZ is considered a novel mechanism of action, enhancing the appeal of TXA709 as an important tool for addressing the public health crisis stemming from the growing threat of antibiotic resistance.
TAXIS Pharmaceuticals develops novel antibiotics to combat multidrug-resistant bacteria. TAXIS has identified and patented multiple new classes of proprietary antibiotic agents that exploit a novel mechanism of bactericidal action distinct from any other antibiotic in clinical use today. For more information visit www.TAXISpharma.com.
973-442-1555 ext. 115
Logo - http://photos.prnewswire.com/prnh/20160906/404552LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-grants-special-designation-to-taxis-pharmaceuticals-experimental-antibiotic-300323341.html
SOURCE TAXIS Pharmaceuticals